Moleculin Biotech (MBRX) said Thursday that certain holders of its existing warrants have agreed to exercise their holdings to purchase about 5.8 million shares of the company at a reduced exercise price of $1 per share.
The company said gross proceeds from the exercise of warrants is expected to total $5.8 million.
In consideration for the exercise of warrants for cash, Moleculin said it will issue new unregistered warrants to buy nearly 11.7 million shares, which will be immediately exercisable at $0.75 per share.
The transaction is expected to close by Friday and net proceeds would be used for working capital and general corporate purposes, the company said.
Price: 2.21, Change: +1.79, Percent Change: +426.19
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。